Quarterly report [Sections 13 or 15(d)]

Consolidated Statements of Stockholders' Equity

v3.25.3
Consolidated Statements of Stockholders' Equity - USD ($)
shares in Thousands, $ in Millions
Total
2025 Q1 Dividends
2025 Q2 Dividends - April
2025 Q2 Dividends - June
2024 Q1 Dividends
2024 Q2 Dividends - April
2024 Q2 Dividends - June
Common Stock
Treasury Stock
Additional Paid-in Capital
Retained Earnings
NCI
Redeemable NCI
Common Stock, Shares, Outstanding, Beginning of Period at Dec. 31, 2023               237,000          
Treasury Stock, Shares, Beginning of Period at Dec. 31, 2023                 40,900        
Stockholders' Equity, Beginning of Period at Dec. 31, 2023 $ 9,020             $ 1 $ (3,864) $ 4,377 $ 4,546 $ 3,960  
Redeemable NCI, Equity, Carrying Amount at Dec. 31, 2023 [1]                         $ 0
Increase (Decrease) in Stockholders' Equity [Roll Forward]                          
Net Income (Loss), Including Portion Attributable to Non Redeemable NCI 839                   502 337  
Dividends declared (103)                   (103)    
Shares repurchased, at cost and inclusive of excise taxes, shares               (7,500) 7,500        
Shares repurchased, at cost and inclusive of excise taxes (1,203)               $ (1,203)        
Distributions to NCI (253)                     (253)  
Contributions from redeemable NCI [1]                         4
Vesting of share-based compensation awards, shares               600          
Share-based compensation 34                 34      
Issued shares withheld from employees related to share-based compensation, at cost (40)                 (40)      
Common Stock, Shares, Outstanding, End of Period at Mar. 31, 2024               230,100          
Treasury Stock, Shares, End of Period at Mar. 31, 2024                 48,400        
Stockholders' Equity, End of Period at Mar. 31, 2024 8,294             $ 1 $ (5,067) 4,371 4,945 4,044  
Redeemable NCI, Equity, Carrying Amount at Mar. 31, 2024 [1]                         4
Increase (Decrease) in Stockholders' Equity [Roll Forward]                          
Common Stock, Dividends, Per Share, Declared         $ 0.435                
Common Stock, Shares, Outstanding, Beginning of Period at Dec. 31, 2023               237,000          
Treasury Stock, Shares, Beginning of Period at Dec. 31, 2023                 40,900        
Stockholders' Equity, Beginning of Period at Dec. 31, 2023 $ 9,020             $ 1 $ (3,864) 4,377 4,546 3,960  
Redeemable NCI, Equity, Carrying Amount at Dec. 31, 2023 [1]                         0
Increase (Decrease) in Stockholders' Equity [Roll Forward]                          
Shares repurchased, at cost and inclusive of excise taxes, shares 12,240                        
Contributions from redeemable NCI $ 6                        
Common Stock, Shares, Outstanding, End of Period at Sep. 30, 2024               225,400          
Treasury Stock, Shares, End of Period at Sep. 30, 2024                 53,100        
Stockholders' Equity, End of Period at Sep. 30, 2024 9,347             $ 1 $ (5,853) 4,436 6,518 4,245  
Redeemable NCI, Equity, Carrying Amount at Sep. 30, 2024 [1]                         6
Common Stock, Shares, Outstanding, Beginning of Period at Mar. 31, 2024               230,100          
Treasury Stock, Shares, Beginning of Period at Mar. 31, 2024                 48,400        
Stockholders' Equity, Beginning of Period at Mar. 31, 2024 8,294             $ 1 $ (5,067) 4,371 4,945 4,044  
Redeemable NCI, Equity, Carrying Amount at Mar. 31, 2024 [1]                         4
Increase (Decrease) in Stockholders' Equity [Roll Forward]                          
Net Income (Loss), Including Portion Attributable to Non Redeemable NCI 1,162                   880 282  
Dividends declared (200)                   (200)    
Shares repurchased, at cost and inclusive of excise taxes, shares               (3,100) 3,100        
Shares repurchased, at cost and inclusive of excise taxes (501)               $ (501)        
Distributions to NCI (198)                     (198)  
Contributions from redeemable NCI [1]                         2
Share-based compensation 36                 36      
Issued shares withheld from employees related to share-based compensation, at cost (1)                 (1)      
Common Stock, Shares, Outstanding, End of Period at Jun. 30, 2024               227,000          
Treasury Stock, Shares, End of Period at Jun. 30, 2024                 51,500        
Stockholders' Equity, End of Period at Jun. 30, 2024 8,592             $ 1 $ (5,568) 4,406 5,625 4,128  
Redeemable NCI, Equity, Carrying Amount at Jun. 30, 2024 [1]                         6
Increase (Decrease) in Stockholders' Equity [Roll Forward]                          
Common Stock, Dividends, Per Share, Declared           $ 0.435 $ 0.435            
Net Income (Loss), Including Portion Attributable to Non Redeemable NCI $ 1,207                   893 314  
Shares repurchased, at cost and inclusive of excise taxes, shares 1,580             (1,600) 1,600        
Shares repurchased, at cost and inclusive of excise taxes $ (285)               $ (285)        
Distributions to NCI (197)                     (197)  
Share-based compensation 34                 34      
Issued shares withheld from employees related to share-based compensation, at cost (4)                 (4)      
Common Stock, Shares, Outstanding, End of Period at Sep. 30, 2024               225,400          
Treasury Stock, Shares, End of Period at Sep. 30, 2024                 53,100        
Stockholders' Equity, End of Period at Sep. 30, 2024 $ 9,347             $ 1 $ (5,853) 4,436 6,518 4,245  
Redeemable NCI, Equity, Carrying Amount at Sep. 30, 2024 [1]                         6
Common Stock, Shares, Outstanding, Beginning of Period at Dec. 31, 2024               224,000          
Treasury Stock, Shares, Beginning of Period at Dec. 31, 2024 54,700               54,700        
Stockholders' Equity, Beginning of Period at Dec. 31, 2024 $ 10,053             $ 1 $ (6,136) 4,452 7,382 4,354  
Redeemable NCI, Equity, Carrying Amount at Dec. 31, 2024 7                       7 [1]
Increase (Decrease) in Stockholders' Equity [Roll Forward]                          
Net Income (Loss), Including Portion Attributable to Non Redeemable NCI 670                   353 317  
Net Income (Loss) Attributable to Redeemable NCI [1]                         (2)
Dividends declared (113)                   (113)    
Shares repurchased, at cost and inclusive of excise taxes, shares               (1,600) 1,600        
Shares repurchased, at cost and inclusive of excise taxes (352)               $ (352)        
Accretion of redeemable non-controlling interest, net of tax [2] (2)                   (2)   2 [1]
Distributions to NCI (200)                     (200)  
Contributions from redeemable NCI [1]                         38
Vesting of share-based compensation awards, shares               400          
Share-based compensation 40                 40      
Issued shares withheld from employees related to share-based compensation, at cost (44)                 (44)      
Common Stock, Shares, Outstanding, End of Period at Mar. 31, 2025               222,800          
Treasury Stock, Shares, End of Period at Mar. 31, 2025                 56,300        
Stockholders' Equity, End of Period at Mar. 31, 2025 $ 10,052             $ 1 $ (6,488) 4,448 7,620 4,471  
Redeemable NCI, Equity, Carrying Amount at Mar. 31, 2025 [1]                         45
Common Stock, Shares, Outstanding, Beginning of Period at Dec. 31, 2024               224,000          
Treasury Stock, Shares, Beginning of Period at Dec. 31, 2024 54,700               54,700        
Stockholders' Equity, Beginning of Period at Dec. 31, 2024 $ 10,053             $ 1 $ (6,136) 4,452 7,382 4,354  
Redeemable NCI, Equity, Carrying Amount at Dec. 31, 2024 $ 7                       7 [1]
Increase (Decrease) in Stockholders' Equity [Roll Forward]                          
Shares repurchased, at cost and inclusive of excise taxes, shares 7,370                        
Contributions from redeemable NCI $ 108                        
Common Stock, Shares, Outstanding, End of Period at Sep. 30, 2025               217,200          
Treasury Stock, Shares, End of Period at Sep. 30, 2025 62,100               62,100        
Stockholders' Equity, End of Period at Sep. 30, 2025 $ 11,343             $ 1 $ (7,826) 4,507 10,067 4,594  
Redeemable NCI, Equity, Carrying Amount at Sep. 30, 2025 118                       118 [1]
Common Stock, Shares, Outstanding, Beginning of Period at Mar. 31, 2025               222,800          
Treasury Stock, Shares, Beginning of Period at Mar. 31, 2025                 56,300        
Stockholders' Equity, Beginning of Period at Mar. 31, 2025 10,052             $ 1 $ (6,488) 4,448 7,620 4,471  
Redeemable NCI, Equity, Carrying Amount at Mar. 31, 2025 [1]                         45
Increase (Decrease) in Stockholders' Equity [Roll Forward]                          
Net Income (Loss), Including Portion Attributable to Non Redeemable NCI 1,899                   1,626 273  
Net Income (Loss) Attributable to Redeemable NCI [1]                         (2)
Dividends declared (222)                   (222)    
Shares repurchased, at cost and inclusive of excise taxes, shares               (1,400) 1,400        
Shares repurchased, at cost and inclusive of excise taxes (310)               $ (310)        
Accretion of redeemable non-controlling interest, net of tax [2] (3)                   (3)   4 [1]
Distributions to NCI (200)                     (200)  
Contributions from redeemable NCI [1]                         11
Vesting of share-based compensation awards, shares               100          
Share-based compensation 37                 37      
Issued shares withheld from employees related to share-based compensation, at cost (2)                 (2)      
Common Stock, Shares, Outstanding, End of Period at Jun. 30, 2025               221,500          
Treasury Stock, Shares, End of Period at Jun. 30, 2025                 57,700        
Stockholders' Equity, End of Period at Jun. 30, 2025 11,251             $ 1 $ (6,798) 4,483 9,021 4,544  
Redeemable NCI, Equity, Carrying Amount at Jun. 30, 2025 [1]                         58
Increase (Decrease) in Stockholders' Equity [Roll Forward]                          
Common Stock, Dividends, Per Share, Declared   $ 0.500 $ 0.500 $ 0.500                  
Net Income (Loss), Including Portion Attributable to Non Redeemable NCI $ 1,299                   1,049 250  
Net Income (Loss) Attributable to Redeemable NCI [1]                         (3)
Shares repurchased, at cost and inclusive of excise taxes, shares 4,370             (4,400) 4,400        
Shares repurchased, at cost and inclusive of excise taxes $ (1,028)               $ (1,028)        
Accretion of redeemable non-controlling interest, net of tax [2] (3)                   (3)   4 [1]
Distributions to NCI (200)                     (200)  
Contributions from redeemable NCI [1]                         59
Vesting of share-based compensation awards, shares               100          
Share-based compensation 28                 28      
Issued shares withheld from employees related to share-based compensation, at cost $ (4)                 (4)      
Common Stock, Shares, Outstanding, End of Period at Sep. 30, 2025               217,200          
Treasury Stock, Shares, End of Period at Sep. 30, 2025 62,100               62,100        
Stockholders' Equity, End of Period at Sep. 30, 2025 $ 11,343             $ 1 $ (7,826) $ 4,507 $ 10,067 $ 4,594  
Redeemable NCI, Equity, Carrying Amount at Sep. 30, 2025 $ 118                       $ 118 [1]
[1] Redeemable NCI represents the economic interest held by a third party in one of our consolidated VIEs that is redeemable for cash under certain circumstances, including those that are outside of our control. As such, the economic interest is not a component of permanent equity on our Consolidated Balance Sheets.
[2] Amount in retained earnings presented net of tax.